The S&P500 (SP500) closed in the green on Friday, with companies including Walmart, Nvidia and Gap stealing the limelight ...

UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second ...

Needham has downgraded Biogen (NASDAQ:BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Needham & Company LLC from a “buy” ...

Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...